Axonics Inc logo

AXNX

Axonics Inc

$72.98

Earnings Summary

Revenue
$68.98Mn
Net Profits
$-21.44Mn
Net Profit Margins
-31.09%

Highlights

Revenue:

Axonics Inc’s revenue jumped 50.38% since last year same period to $68.98Mn in the Q2 2022. On a quarterly growth basis, Axonics Inc has generated 42.46% jump in its revenue since last 3-months.

Net Profits:

Axonics Inc’s net profit jumped 14.73% since last year same period to $-21.44Mn in the Q2 2022. On a quarterly growth basis, Axonics Inc has generated 5.4% jump in its net profits since last 3-months.

Net Profit Margins:

Axonics Inc’s net profit margin jumped 43.3% since last year same period to -31.09% in the Q2 2022. On a quarterly growth basis, Axonics Inc has generated 33.6% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Axonics Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.48
EPS Estimate Current Year
-0.48

Highlights

EPS Estimate Current Quarter:

Axonics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.48 - a 11.11% jump from last quarter’s estimates.

EPS Estimate Current Year:

Axonics Inc’s earning per share (EPS) estimates for the current year stand at -0.48.

Key Ratios

Key ratios of the Axonics Inc post its Q2 2022 earnings

Earning Per Share (EPS)
-0.47
Return on Assets (ROA)
-0.08
Return on Equity (ROE)
-0.16
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Axonics Inc’s earning per share (EPS) jumped 20.34% since last year same period to -0.47 in the Q2 2022. This indicates that the Axonics Inc has generated 20.34% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Axonics Inc’s return on assets (ROA) stands at -0.08.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Axonics Inc’s return on equity (ROE) stands at -0.16.

Dividend Per Share (DPS):

Axonics Inc declared 0 dividend per share during the earnings announcement for Q2 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-08-01
-0.54
-0.47
12.96%
2022-05-05
-0.63
-0.5
20.63%

Company Information

Based in Irvine, Calif., Axonics has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for patients with bladder and bowel dysfunction, and through its acquisition of Bulkamid®, offers a best-in-class urethral bulking agent for women with stress urinary incontinence. These conditions significantly impact quality of life. Overactive bladder affects an estimated 87 million adults in the U.S. and Europe, with an additional 40 million adults estimated to suffer from fecal incontinence. Stress urinary incontinence affects an estimated 20 million women in the U.S. alone. Axonics' clinically proven products are offered at hundreds of medical centers across the U.S. and abroad. Reimbursement coverage is well established in the U.S. and is a covered service in most European countries.

Organisation
Axonics Inc
Headquarters
Irvine, California, US
Employees
416
Industry
Health Technology
CEO
Raymond Cohen